The facial injectable market is expected to expand at a CAGR of 8.8 per cent, from 2021 to 2028

As per the market reports, the global facial injectable market size is expected to reach US$ 27.7 billion by 2028 and is projected to expand at a CAGR of 8.8 per cent from 2021-2028. The Asia Pacific region is functioning as a key revenue-generating area. India, which has a growing focus on aesthetics, will be a major market player and will back the overall growth. It will also bring opportunities for collagen, hyaluronic acid, botulinum toxin type A, calcium hydroxylapatite, and polymer fillers. The aesthetics segment is predicted to be the fastest-growing market segment over the forecast period. This is primary due to the increase in demand of facial injectable as these are substance used to reduce wrinkles caused by ageing and restore volume and fullness in the face; they are injected directly beneath the skin surface. The increasing importance given to anti-ageing in developing countries and the non-invasive nature of injectable will drive and sustain this sectors market growth. Botulinum toxin type A will continue to lead the market throughout the forecast period, as one of the most popularly used minimally invasive procedures.

Unfortunately, with second and third lockdowns being enforced globally, elective surgeries might be put on hold once again; surgeons are consulting their patients via telemedicine. However, when surgeries go back to full swing, in the long run, surgeons predict changes in the way procedures will be carried out.